Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2005 1
2006 1
2007 2
2009 2
2010 1
2011 3
2012 6
2013 12
2014 12
2015 8
2016 14
2017 22
2018 17
2019 15
2020 21
2021 23
2022 14
2023 22
2024 27
2025 36
2026 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Results by year

Filters applied: . Clear all
Page 1
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment.
Burnett JR, Hooper AJ. Burnett JR, et al. Expert Opin Investig Drugs. 2023 Jul-Dec;32(10):873-878. doi: 10.1080/13543784.2023.2267972. Epub 2023 Nov 6. Expert Opin Investig Drugs. 2023. PMID: 37815341 Review.
Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased risk of ASCVD events. ...EXPERT OPINION: MK-0616 is a potent, oral macrocyclic peptide inhibitor of PCSK9 that is not only able t …
Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased ris …
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Ballantyne CM, et al. JAMA. 2026 Jan 13;335(2):129-139. doi: 10.1001/jama.2025.20620. JAMA. 2026. PMID: 41206969 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy. ...
OBJECTIVE: To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs plac …
Genetic and molecular architecture of familial hypercholesterolemia.
Abifadel M, Boileau C. Abifadel M, et al. J Intern Med. 2023 Feb;293(2):144-165. doi: 10.1111/joim.13577. Epub 2022 Oct 17. J Intern Med. 2023. PMID: 36196022 Free PMC article. Review.
It is one of the most frequently inherited diseases due to mutations, for autosomal dominant forms, in either of the LDLR, APOB, and PCSK9 genes or possibly a few mutations in the APOE gene and, for the rare autosomal forms, in the LDLRAP1 gene. The discovery of the …
It is one of the most frequently inherited diseases due to mutations, for autosomal dominant forms, in either of the LDLR, APOB, and …
Familial hypercholesterolaemia.
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Defesche JC, et al. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. Nat Rev Dis Primers. 2017. PMID: 29219151 Review.
Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor, although mutations in other genes coding for proteins involved in cholesterol metabolism or LDLR function and processing, such as APOB and PCSK9, can also be causative, al …
Most cases are caused by autosomal dominant mutations in LDLR, which encodes the LDL receptor, although mutations in other genes coding for …
Familial Hypercholesterolemia: Genes and Beyond.
Warden BA, Fazio S, Shapiro MD. Warden BA, et al. 2024 Sep 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2024 Sep 23. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 26844336 Free Books & Documents. Review.
Genetic loci involved in ADH include the LDLR, which codes for the LDL receptor (LDLR), APOB, which codes for apolipoprotein B-100 (apoB-100), the major protein component of LDL, PCSK9, which codes for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9 …
Genetic loci involved in ADH include the LDLR, which codes for the LDL receptor (LDLR), APOB, which codes for apolipoprotein B-100 ( …
Familial Hypercholesterolemia.
Ison HE, Clarke SL, Knowles JW. Ison HE, et al. 2014 Jan 2 [updated 2025 Jan 30]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. 2014 Jan 2 [updated 2025 Jan 30]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. PMID: 24404629 Free Books & Documents. Review.
The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants that impair binding of LDL-C to the LDL receptor), LDLR, or PCSK9 (gain of function); or rarely, identification of biallelic pathoge …
The molecular diagnosis of FH can be established by identification of heterozygous or biallelic pathogenic variants in APOB (variants …
Lipid-lowering in diabetes: An update.
Chait A, Eckel RH, Vrablik M, Zambon A. Chait A, et al. Atherosclerosis. 2024 Jul;394:117313. doi: 10.1016/j.atherosclerosis.2023.117313. Epub 2023 Oct 6. Atherosclerosis. 2024. PMID: 37945448 Free article. Review.
However, since many patients fail to attain the low levels of low-density lipoproteins (LDL) recommended in these guidelines, supplemental therapy, such as the addition of ezetimibe, bempedoic acid or PCSK9 inhibitors, is often required to reach LDL goals. As a resu …
However, since many patients fail to attain the low levels of low-density lipoproteins (LDL) recommended in these guidelines, supplemental t …
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J, Zhang W, Zhu P, Zhuo M, Ballantyne CM; CORALreef Lipids Investigators. Navar AM, et al. N Engl J Med. 2026 Feb 5;394(6):529-539. doi: 10.1056/NEJMoa2511002. N Engl J Med. 2026. PMID: 41879224 Clinical Trial.
BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. ...CONCLUSIONS: Among participants who ha …
BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce …
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Michaeli DT, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):477-495. doi: 10.1007/s40256-023-00594-5. Epub 2023 Jul 24. Am J Cardiovasc Drugs. 2023. PMID: 37486464 Free PMC article. Review.
Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, fibrates as peroxisome proliferator receptor alp …
Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein con …
Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L, Kayikcioglu M. Tokgozoglu L, et al. Curr Cardiol Rep. 2021 Sep 4;23(10):151. doi: 10.1007/s11886-021-01565-5. Curr Cardiol Rep. 2021. PMID: 34480646 Review.
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and the LDL-receptor adaptor protein 1 (LDLRAP1) genes cause FH. ...Getting to LDL-C goals is p …
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein conver …
263 results